Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Séverine Vermeire, Marc Ferrante et al.|Clinical Gastroenterology and Hepatology|2018Cited by 158
Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission RatesBram Verstockt, Marc Ferrante, Erwin Dreesen et al.|Journal of Crohn s and Colitis|2019Cited by 123
Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative ColitisDahham Alsoud, Bram Verstockt, Gert De Hertogh et al.|Journal of Crohn s and Colitis|2022Cited by 27
P442 Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative ColitisDahham Alsoud, Bram Verstockt, Gert De Hertogh et al.|Journal of Crohn s and Colitis|2022Cited by 4